271 related articles for article (PubMed ID: 21965226)
1. Physiological effects of roflumilast at rest and during exercise in COPD.
O'Donnell DE; Bredenbröker D; Brose M; Webb KA
Eur Respir J; 2012 May; 39(5):1104-12. PubMed ID: 21965226
[TBL] [Abstract][Full Text] [Related]
2. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD.
Guenette JA; Raghavan N; Harris-McAllister V; Preston ME; Webb KA; O'Donnell DE
Respir Med; 2011 Dec; 105(12):1836-45. PubMed ID: 21917440
[TBL] [Abstract][Full Text] [Related]
3. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
6. Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD.
Guenette JA; Webb KA; O'Donnell DE
Respir Med; 2013 May; 107(5):708-16. PubMed ID: 23421968
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
[TBL] [Abstract][Full Text] [Related]
8. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.
Rogliani P; Ora J; Puxeddu E; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2018 Apr; 49():20-26. PubMed ID: 29294360
[TBL] [Abstract][Full Text] [Related]
9. Improved respiratory system conductance following bronchodilator predicts reduced exertional dyspnoea.
Diba C; King GG; Berend N; Salome CM
Respir Med; 2011 Sep; 105(9):1345-51. PubMed ID: 21482091
[TBL] [Abstract][Full Text] [Related]
10. Effect of obesity on respiratory mechanics during rest and exercise in COPD.
Ora J; Laveneziana P; Wadell K; Preston M; Webb KA; O'Donnell DE
J Appl Physiol (1985); 2011 Jul; 111(1):10-9. PubMed ID: 21350021
[TBL] [Abstract][Full Text] [Related]
11. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD.
Peters MM; Webb KA; O'Donnell DE
Thorax; 2006 Jul; 61(7):559-67. PubMed ID: 16467067
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
[TBL] [Abstract][Full Text] [Related]
14. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
Luo J; Wang K; Liu D; Liang BM; Liu CT
Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
[TBL] [Abstract][Full Text] [Related]
15. Modulation of operational lung volumes with the use of salbutamol in COPD patients accomplishing upper limbs exercise tests.
Porto EF; Castro AA; Nascimento O; Oliveira RC; Cardoso F; Jardim JR
Respir Med; 2009 Feb; 103(2):251-7. PubMed ID: 18930646
[TBL] [Abstract][Full Text] [Related]
16. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.
O'Donnell DE; Voduc N; Fitzpatrick M; Webb KA
Eur Respir J; 2004 Jul; 24(1):86-94. PubMed ID: 15293609
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
18. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD.
O'Donnell DE; Hamilton AL; Webb KA
J Appl Physiol (1985); 2006 Oct; 101(4):1025-35. PubMed ID: 16675610
[TBL] [Abstract][Full Text] [Related]
19. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease.
O'Donnell DE; Lam M; Webb KA
Am J Respir Crit Care Med; 1998 Nov; 158(5 Pt 1):1557-65. PubMed ID: 9817708
[TBL] [Abstract][Full Text] [Related]
20. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity.
Deesomchok A; Webb KA; Forkert L; Lam YM; Ofir D; Jensen D; O'Donnell DE
COPD; 2010 Dec; 7(6):428-37. PubMed ID: 21166631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
